Clinical Trial Update: Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz [NA]

View source ↗

Summary

A clinical trial update suggests vitamin D and calcium supplementation may attenuate bone loss in HIV-infected patients on tenofovir disoproxil fumarate, lamivu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Osteopenia
• Osteoporosis

Drugs mentioned

• Calcium (Calcium)
• EFAVIRENZ (efavirenz)
• Emtricitabine (Emtricitabine)
• Lamivudine (lamivudine)
• TENOFOVIR DISOPROXIL FUMARATE (tenofovir disoproxil fumarate)
• Vitamin D (Cholecalciferol)

Snippet

Sponsor: Mahidol University | Conditions: Bone Density | NA | Status: UNKNOWN